An overview of intranasal drug delivery systems for Alzheimer’s disease

Zeenath Unnissa; Maher Unissa; Muznah Muzaffar Hussain; Syed Eshaan Ali

doi:10.18203/2319-2003.ijbcp20253380

Authors

Zeenath Unnissa Department of Pharmacy Practice, Deccan School of Pharmacy, Hyderabad, Telangana, India
Maher Unissa Department of Pharmacy Practice, Sultan –ul- Uloom College of Pharmacy, Hyderabad, Telangana, India
Muznah Muzaffar Hussain Department of Pharmacy Practice, Deccan School of Pharmacy, Hyderabad, Telangana, India
Syed Eshaan Ali Department of Pharmacy Practice, Deccan School of Pharmacy, Hyderabad, Telangana, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20253380

Keywords:

Blood-brain barrier, Central nervous system, Intranasal, Nanoparticle, Neurodegenerative, Permeation enhancer, Protein

Abstract

Alzheimer’s disease is a neurodegenerative condition with severe consequences interfering with patient quality of life. It is a chronic and irreversible cognitive brain condition in which memory and thinking capacities are severely impaired to the point of preventing the completion of daily activities, because of physical and cognitive limitations. The standard treatment is administered orally; however, it has significant disadvantages, including poor bioavailability, rapid metabolism, restricted uptake into the brain and severe side effects. The intranasal route has been proposed as a promising alternative to deliver drugs and improve the Alzheimer's disease treatment. Still, there is not a clear alternative delivery system available in the market with advantageous bioavailability and safety. The aim of this review is to perform an overview on the strategies for intranasal drug delivery in Alzheimer’s disease management. The advantages and disadvantages of this delivery route and the delivery systems developed so far are discussed. A special focus is given on the use of permeation enhancers, the types of intranasal drug delivery devices, as well as possible toxicity concerns.

Metrics

Metrics Loading ...

References

Weller J, Budson A. Current understanding of Alzheimer’s disease diagnosis and treatment. Research. 2018;7:1000.

Crous-Bou M, Minguillón C, Gramunt N, Molinuevo JL. Alzheimer’s disease prevention: from risk factors to early intervention. Alzheimer's Res Ther. 2017;9(1):71.

Silva MV, Loures CD, Alves LC, De Souza LC, Borges KB, Carvalho MD. Alzheimer’s disease: risk factors and potentially protective measures. J Biomed Sci. 2019;26(1):33.

Trejo-Lopez JA, Yachnis AT, Prokop S. Neuropathology of Alzheimer's disease. Neurotherapeutics. 2022;19(1):173-85.

P.M. Kidd Alzheimer's disease, amnestic mild cognitive impairment and age-associated memory impairment: current understanding and progress toward integrative prevention. Altern Med Rev. 2008;2:13.

Bonferoni MC, Rossi S, Sandri G, Ferrari F, Gavini E, Rassu G, et al. Nanoemulsions for “nose-to-brain” drug delivery. Pharmaceutics. 2019;11(2):84.

Taléns-Visconti R, de Julián-Ortiz JV, Vila-Busó O, Diez-Sales O, Nácher A. Intranasal drug administration in Alzheimer-type dementia: towards clinical applications. Pharmaceutics. 2023;15(5):1399.

Prince M, Wimo A, Guerchet M, Ali GC, Wu YT, Prina M. World Alzheimer report. The global impact of dementia: an analysis of prevalence, incidence, cost and trends (Doctoral dissertation, Alzheimer's Disease International). 2015.

Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, Brayne C, Burns A, Cohen-Mansfield J, Cooper C, Costafreda SG. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. The Lancet. 2020;396(10248):413-46.

Alzheimer’s Association 2018 Alzheimer’s Disease Facts and Figures. Alzheimer’s Dement. 2018;14:367–429.

Thal DR, Rüb U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58(12):1791-800.

Braak H., Braak E. Neuropathological Stageing of Alzheimer-Related Changes. Acta Neuropathol. 1991;82:239–59.

Deo Mr, Sant VP, Parekh SR, Khopade AJ, Banakar UV. Proliposome-based transdermal delivery of levonorgestrel. J Biomat App. 1997;12:77–88.

Singh R, Vyas SP. Topical liposomal system for localized and controlled drug delivery. J DermatoI Sci. 1996;13:107–11.

Martin DB, Udupa N. Nasal drug delivery of gentamycin sulphate. Indian Drugs. 1994;31:365.

Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005;2(1):3-14.

Danielyan L, Schäfer R, von Ameln-Mayerhofer A, Buadze M, Geisler J, Klopfer T, et al. Intranasal delivery of cells to the brain. European J Cell Biol. 2009;88(6):315-24.

Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE, et al. Alzheimer's disease. The Lancet. 2021;397(10284):1577-90.

Polizzi S. Arresting Alzheimer's with Diet and Lifestyle. Oregon State Univ Exten Serv. 2023. Available at: https://extension.oregonstate.edu/sites/extd8/files/catalog/auto/EM9383.pdf. Accessed on 15 January 2025.

Breijyeh Z, Karaman R. Comprehensive review on Alzheimer’s disease: causes and treatment. Molecules. 2020;25(24):5789.

Prince M, Wimo A, Guerchet M, Ali GC, Wu YT, Prina M. World Alzheimer report 2015. The global impact of dementia: an analysis of prevalence, incidence, cost and trends (Doctoral dissertation, Alzheimer's Disease International). 2015.

Parra MA, Butler S, McGeown WJ, Nicholls LA, Robertson DJ. Globalising strategies to meet global challenges: the case of ageing and dementia. J Global Health. 2019;9(2):20310.

Erdő F, Denes L, de Lange E. Age-associated physiological and pathological changes at the blood–brain barrier: A review. J Cerebr Blood Flow Metabol. 2017;37(1):4-24.

Nahal D. Cognitive Disease and Age-Related Cognitive Decline. Stimulus: A Med Human J. 2023;3(1):56.

Di Sefano A, Iannitelli A, Laserra S, Sozio P. Drug delivery strategies for Alzheimer’s disease treatment. Expert Opin Drug Deliv. 2011;8:581–603.

Burns A, Iliffe S. Clinical review: Alzheimer’s disease. British Med J. 2009;338(23):158-63.

Mahajan HS, Mahajan MS, Nerkar PP, Agrawal A. Nanoemulsion-based intranasal drug delivery system of saquinavir mesylate for brain targeting. Drug Deliv. 2014;21:148–54.

Agrawal M, Dethe MR, Ahmed H, Yadav A, Gupta U, Alexander A. Nose-to-brain drug delivery for the treatment of Alzheimer's disease: current advancements and challenges. Expert Opin Drug Del. 2022;19(1):87-102.

Lee D, Minko T. Nanotherapeutics for Nose-to-Brain Drug Delivery: An Approach to Bypass the Blood Brain Barrier. Pharmaceutics. 2021;13(12):2049.

Butani S. Fabrication of an ion-sensitive in situ gel loaded with nanostructured lipid carrier for nose to brain delivery of donepezil. Asian J Pharma. 2018;12(4):293.

Dhas NL, Kudarha RR, Mehta TA. Intranasal Delivery of Nanotherapeutics/ Nanobiotherapeutics for the Treatment of Alzheimer's Disease: A Proficient Approach. Crit Rev Ther Drug Carrier Syst. 2019;36(5):373-447.

Poovaiah N, Davoudi Z, Peng H, Schlichtmann B. Treatment of neurodegenerative disorders through the blood-brain barrier using nanocarriers. Nanoscale. 2018;10(36):16962-83.

Erdő F, Bors LA, Farkas D, Bajza Á, Gizurarson S. Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Res Bull. 2018;143:155-70.

Brannigan RP, Khutoryanskiy VV. Progress and Current Trends in the Synthesis of Novel Polymers with Enhanced Mucoadhesive Properties. Macromol Biosci. 2019;19(10):1900194.

Wang Z, Xiong G, Tsang WC, Schätzlein AG, Uchegbu IF. Nose-to-Brain Delivery. J Pharmacol Exp Ther. 2019;370(3):593-601.

Craft S, Claxton A, Baker LD, Hanson AJ, Cholerton B, Trittschuh EH. Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer's Disease Biomarkers: A Pilot Clinical Trial. J Alzheimers Dis. 2017;57(4):1325-34.

Ross C, Taylor M, Fullwood N, Allsop D. Liposome delivery systems for the treatment of Alzheimer's disease. Int J Nanomedicine. 2018;13:8507-22.

Kulkarni P, Rawtani D, Barot T. Design, development and in-vitro/in-vivo evaluation of intranasally delivered Rivastigmine and N-Acetyl Cysteine loaded bifunctional niosomes for applications in combinative treatment of Alzheimer's disease. Eur J Pharm Biopharm. 2021;163:1-15.

Gharbavi M, Amani J, Kheiri-Manjili H, Danafar H, Sharafi A. Niosome: A Promising Nanocarrier for Natural Drug Delivery through Blood-Brain Barrier. Adv Pharmacol Sci. 2018;2018:6847971

de Souza IFF, Dos Santos TQ, Placido RV. The liquid crystalline phase behaviour of a nasal formulation modifies the brain disposition of donepezil in rats in the treatment of Alzheimer's disease. Colloids Surf B Biointerfaces. 2021;203:111721.

Kaur A, Nigam K, Bhatnagar I, Sukhpal H, Awasthy S, Shankar S. Treatment of Alzheimer's diseases using donepezil nanoemulsion: an intranasal approach. Drug Deliv Transl Res. 2020;10(6):1862-75.

Costa C, Moreira JN, Amaral MH, Sousa Lobo JM, Silva AC. Nose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisis. J Cont Rel. 2019;295:187-200.

Gadhave DG, Kokare CR. Nanostructured lipid carriers engineered for intranasal delivery of teriflunomide in multiple sclerosis: optimization and in vivo studies. Drug Dev Ind Pharm. 2019;45(5):839-51.

Desfrançois C, Auzély R, Texier I. Lipid Nanoparticles and Their Hydrogel Composites for Drug Delivery: A Review. Pharmaceuticals (Basel). 2018;11(4):118.

Mendez MF. Early-onset Alzheimer's disease: non amnestic subtypes and type 2 AD. Arch Med Res. 2012;43(8):677-85.

Li X, Feng X, Sun X, Hou N, Han F, Liu Y. Global, regional and national burden of Alzheimer's disease and other dementias, 1990-2019. Front Aging Neurosci. 2022;14:937486.

Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE, et al. Alzheimer's disease. Lancet. 2021;397(10284):1577-90.

Villarejo Galende A, Eimil Ortiz M, Llamas Velasco S. Report by the Spanish Foundation of the Brain on the social impact of Alzheimer disease and other types of dementia. Neurologia (Engl Ed). 2021;36(1):39-49.

Hallschmid M. Intranasal insulin. J Neuroendocrinol. 2021;33(4):12934.

Rao YL, Ganaraja B, Joy T, Pai MM, Ullal SD, Murlimanju BV. Neuroprotective effects of resveratrol in Alzheimer's disease. Front Biosci. 2020;12(1):139-49.

Tripathi S, Gupta U, Ujjwal RR, Yadav AK. Nano-lipidic formulation and therapeutic strategies for Alzheimer’s disease via intranasal route. J Microencap. 2021;38(7-8):572-93.

Terstappen GC, Meyer AH, Bell RD, Zhang W. Strategies for delivering therapeutics across the blood–brain barrier. Nature Rev Drug Disc. 2021;20(5):362-83.

Dando SJ, Mackay-Sim A, Norton R, Currie BJ. Pathogens penetrating the central nervous system: infection pathways and the cellular and molecular mechanisms of invasion. Clin Microbiol Rev. 2014;27(4):691-726.

Selvaraj K, Gowthamarajan, K, Karri VVSR. Nose to brain transport pathways an overview: potential of nanostructured lipid carriers in nose to brain targeting. Artificial Cells, Nanomed Biotechnol. 2017;46(8):2088–95.

Dhas N, Mehta T, Sharma S, Garkal A, Yadav D, Hariharan K. Intranasal gene therapy for the treatment of neurological disorders. InDirect Nose-to-Brain Drug Delivery 2021: 351-87.

Patel MM, Patel BM. Crossing the blood-brain barrier: recent advances in drug delivery to the brain. CNS Drugs. 2017;31(2):109-33.

Hammarlund-Udenaes M, Fridén M, Syvänen S, Gupta A. On the rate and extent of drug delivery to the brain. Pharm Res. 2008;25(8):1737-50.

Binda A, Murano C, Rivolta I. Innovative Therapies and Nanomedicine Applications for the Treatment of Alzheimer’s Disease: A State-of-the-Art (2017–2020). Int J Nanomedicine. 2020;15:6113-35.

Hippius H, Neundörfer G. The discovery of Alzheimer’s disease. Dial Clin Neurosci. 2003;5(1):101–8.

Waring MJ. Defining optimum lipophilicity and molecular weight ranges for drug candidates-molecular weight dependent lower logD limits based on permeability. Bioorg Med Chem Lett. 2009;19(10):2844-51.

Ahmad N, Al-Subaiec AM, Ahmad R. Brain-targeted glycyrrhizic-acid-loaded surface decorated nanoparticles for treatment of cerebral ischaemia and its toxicity assessment. Artif Cells Nanomed Biotechnol. 2019;47(1):475-90.

Rege SD, Geetha T, Griffin GD, Broderick TL, Babu JR. Neuroprotective effects of resveratrol in Alzheimer disease pathology. Front Aging Neurosci. 2014;6:218.

Andrade S, Ramalho MJ, Pereira MDC, Loureiro JA. Resveratrol brain delivery for neurological disorders prevention and treatment. Front Pharmacol. 2018;9:1261.

Bruinsmann FA, Richter Vaz G, de Cristo Soares Alves A. Nasal drug delivery of anticancer drugs for the treatment of glioblastoma: preclinical and clinical trials. Molecules. 2019;24(23):1-32.

Mukherjee S, Baidoo JNE, Sampat S. Liposomal tricurin, a synergistic combination of curcumin, epicatechin gallate and resveratrol, repolarizes tumor-associated microglia/macrophages and eliminates glioblastoma (GBM) and GBM Stem Cells. Molecules. 2018;23(1):1-21.

Duchi S, Ovadia H, Touitou E. Nasal administration of drugs as a new non-invasive strategy for efficient treatment of multiple sclerosis. J Neuroimmunol. 2013;258(2):32-40.